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Hematopatološki i citogenetski nalaz kod bolesnika sa hroničnom mijeloidnom
leukemijom lečenih imatinib-mesilatom: 2,5 godine iskustva
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Clinical Center Niš, Clinic of  Haematology and Clinical Immunology,
Niš, Serbia
Abstract
Background/Aim. Imatinib mesylate, a tyrosine kinase in-
hibitor with specific activity against the breakpoint cluster
region - Abelson murine leukemia (BCR-ABL) tyrosine ki-
nase has been developed for treatment of chronic myeloge-
nous leukemia (CML). Its hematologic and cytogenetic ef-
fects have been evaluated in a series of clinical trials. The
aim of this study was to report hematologic and cytogenetic
response in CML patients during the treatment with
imatinib mesylate.  Methods. A total of 21 patients were
treated and observed from July 2006 to December 2008.
The median time from CML diagnosis was no more than 12
months, so all the patients received previous treatment with
hydroxyurea for which the median time was 3 months. The
patients received imatinib mesylate in an effective oral dose
of 400 to 800 mg daily, which was followed with peripheral
blood counts, bone marrow examination, and cytogenetic
studies at 6, 12, 18 and 24 months. Results. Complete he-
matologic responses were reported for 19 (90.48%) of 21
patients studied. Among 19 patients who had a response, 16
(86%) did so within 3 months. The best cytogenetic re-
sponse rate at any time during the study treatment with
imatinib mesylate, among 14 patients in which cytogenetic
response evaluated was: complete cytogenetic response in 7
(50%) patients, partial cytogenetic response in 6 (42.9%)
patients and minor cytogenetic response in 1 (7.1%) patient.
No patients had progressed to accelerated or blastic phase.
The most frequent adverse effects that seemed to be related
to treatment with imatinib mesylate were edema and mus-
culosceletal pain; overall, most were mild. Only one patient
discontinued treatment because of hematologic toxic ef-
fects. Conclusion. The results obtained in this study con-
firm that imatinib mesylate induces a complete hematologi-
cal and cytogenetic response in a high percentage of pa-
tients with chronic-phase CML.
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Apstrakt
Uvod/Cilj. Imatinib-mesilat, inhibitor tirozin-kinaze sa
specifičnom aktivnošću prema breakpoint cluster region  –
 Abelson murine leukemia (BCR-ABL) tirozin-kinazi, razvijen
je za lečenje hronične mijeloidne leukemije (HML). Njegov
hematološki i citogenetski efekat bio je procenjivan u seriji
kliničkih studija. Cilj ove studije bio je da se izvesti o hemato-
loškom i citogenetskom odgovoru kod bolesnika sa HML
tokom lečenja imatinib-mesilatom. Metode. Ukupno 21
bolesnik bio je lečen i praćen u periodu od jula 2006. do de-
cembra 2008. Srednje vreme od dijagnoze HML nije bilo
duže od 12 meseci tako da su svi bolesnici dobijali prethod-
ni tretman sa hidroksiureom u trajanju od prosečno 3 mese-
ca. Bolesnici su dobijali imatinib-mesilat u efektivnoj oralnoj
dozi od 400 do 800 mg dnevno, što je bilo praćeno određi-
vanjem kompletne krvne slike, ispitivanjem koštane srži i
citogenetskim ispitivanjem nakon  6, 12, 18 i 24 meseca.
Rezultati. Kompletan hematološki odgovor bio je registro-
van kod  19 (90,48%) od 21 ispitivanog bolesnika. Među 19
bolesnika koji su imali odgovor, 16 (86%) postiglo ga je to-
kom 3 meseca. Najbolja stopa citogenetskog odgovora bilo
kada tokom tretmana imatinib-mesilatom, među 14 bolesni-
ka kod kojih je citogenetski odgovor procenjivan, bila je:
kompletan citogenetski odgovor – sedam (50%) bolesnika,
parcijalni citogenetski odgovor – šest (42,9%) bolesnika i
mali citogenetski odgovor – jedan (7,1%) bolesnik. Nije bilo
bolesnika koji su progredirali u fazu akceleracije ili blastnu
fazu. Najčešći neželjeni efekti koji mogu biti povezani sa le-
čenjem imatinib-mesilatom bili su edemi i muskuloskeletni
bol koji su, ukupno posmatrano, većinom bili blagi. Samo
jedan bolesnik bio je isključen iz lečenja zbog hematološkog
toksičnog efekta. Zaključak. Dobijeni rezultati potvrđuju
da imatinib-mesilat indukuje kompletan hematološki i cito-
genetski odgovor kod visokog procenta bolesnika sa hroni-
čnom fazom HML.
Ključne reči:
leukemija, mijeloidna, hronična; antineoplastici;
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Introduction
Chronic myeloid leukemia (CML) is a clonal disorder
in which cells of the myeloid lineage undergo massive clonal
expansion. The disease progresses through three distinct
phases – chronic phase, accelerated phase and blast crisis –
during which the leukemic clone progressively losses its
ability to differentiate.
The characteristic genetic abnormality of CML, the
Philadelphia (Ph) chromosome, results from a reciprocal
translocation between chromosomes 9 and 22. The molecular
consequence of breakpoint cluster region–Abelson murine
leukemia  (BCR-ABL) gene is a generation of the fusion
protein BCR-ABL, which constitutively activates tyrosine
kinase, present in virtually all patients with CML. For these
reasons, an inhibitor of BCR-ABL tyrosine kinase should be
an effective and selective treatment for CML 
1, 2.
Current therapies include drug regimens with interferon
alpha, hydroxyurea, busulfan, investigational agents and al-
logeneic bone marrow transplantation. Interferon alpha pro-
longs overall survival but has considerable adverse effects.
The rate of hematologic response with these second-line
agents is approximately 50%, but cytogenetic responses are
uncommon 
3. AlloHSCT (hematopoietic stem cell transplan-
tation) is not a first-line treatment choice in patients with
CML, instead imatinib mesylate (IM) is perferred as initial
treatment. AlloHSCT or investigational treatments were rec-
ommended in case of failure, and could be considered in case
of suboptimal response. AlloHSCT should be considered in
all patients younger than 45–50 years, that have not achieved
hematological response, that have no cytogenetic response
after 6 or 12 months of treatment with imatinib mesylate, or
in patients with bad cytogenetic response (Ph-chromosome
> 35%), as well in patients with disease recidive. AlloHSCT
could be offered to patients with low or intermediate the
European Group of Blood and Marrow Transplantation
(EBMT) risk score and in the case of high EBMT risk score
as salvage therapy 
4.
Imatinib mesylate is a potent and selective competitive
inhibitor of BCR-ABL protein tyrosine kinase. Imatinib me-
sylate is the first molecular target therapy for the treatment of
CML. He has demonstrated significant activity in all phases
of Ph positive CML. Daily doses of 400 mg or more of IM
induce durable hematologic responses and high rates of cy-
togenetic responses in nearly all patients with chronic-phase
CML, with minimal toxic effects 
5–7.
Methods
A total of 21 patients were observed and treated from
July 2006 to December 2008. The patients were 18 years of
age or older and had chronic phase, Ph-chromosome positive
CML. The median age of the group was 48.67 years (range
19 to 68).
The patients received an oral dose of 400 mg of IM
daily. Escalation to 800 mg of IM daily was permitted for 1
patient after 6 months and escalation to 600 mg daily was
permitted for 2 patients after 24 months of treatment. A
dose escalation has been required because of failure of the
previous treatment with IM in dose of 400 mg daily (cyto-
genetic refractoriness or cytogenetic relapse). One patient
discontinued treatment with the drug because of hemato-
logic toxic effect.
The chronic phase was defined by the presence of less
than 15 percent blasts in bone marrow, less than 20 percent
basophiles and less than 30 percent blasts plus promyelo-
cytes in the peripheral blood and bone marrow and a platelet
count of at least 100 × 10
9/L. A hematologic response was
defined as 50 percent reduction in the white-cell count from
base line, maintained for at least two weeks. A complete he-
matologic response was defined as a reduction in the white-
cell count to less than 10 × 10
9/L and in the platelet count to
less than 450 × 10
9/L and less than 20 percent basophiles in
peripheral blood, no immature cells in peripheral blood, and
disappearance of all signs and symptoms related to leukemia,
including palpable splenomegaly, maintained for at least four
weeks 
2, 8.
Cytogenetic responses were determined by the percent-
age of cells in metaphase that were positive for the Ph chro-
mosome in the bone marrow. Cytogenetic responses, based
on analysis of average 20 cells in metaphase, were catego-
rized as complete (no cells positive for the Ph chromosome),
partial (1–35% of cells positive for the Ph chromosome), mi-
nor (36–95% of cells positive for the Ph chromosome) and
absent (over 95% of cells positive for the Ph chromosome).
Major responses were defined as complete plus partial re-
sponse. Cytogenetic relapse defined as at least 65 percent Ph-
chromosome–positive cells in metaphase or an increase of at
least 30 percent from the previous study 
2, 8.
A complete blood count and a differential blood count
were obtained weekly for the first 4 weeks, and every 4
weeks after that, while extramedullary involvement was also
evaluated by physical examination. Bone marrow morphol-
ogy and cytogenetic were evaluated every 6 months. Adverse
effects were evaluated at each visit and graded according to
the National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI CTCAE) 
9.
Results
The pretreatment characteristics of the patient included
in the study were typical for patients with chronic-phase
CML and summarized in Table 1.
Among 21 patients with CML that we followed the me-
dian time from previous treatment with hydroxyurea was
3.08 months (range 1–7 months). The median duration of
treatment with IM was 12.64 months (range 5 to 30) while
47.62% of the patients were treated for at least 12 months.
Peripheral blood and bone marrow values at 6, 12, 18
and 24 months in IM treated chronic phase CML patients are
detailed in Table 2.
Complete hematologic responses (CHR) were attained
in 19 of 21 (90.48%) patients treated during 5 months with
IM, while 16 (84%) of those reached CHR in 3 months. Cy-
togenetic response rates to IM therapy at 6, 12, 18 and 24
months are shown in Table 3.Strana 804 VOJNOSANITETSKI PREGLED Volumen 67, Broj 10
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Table 1             
Pretreatment characteristics of the patients
Parameter Values
Age
60 y or older, n (%) 3 (14.3)
median, y (range) 48.6 (19–68)
Male, n (%) 15 (71.4)
Splenomegaly, n (%) 17 (80.9)
Hemoglobin
less than 120 g/L, n (%) 10 (47.6)
median, g/L (range) 120.6 (87–145)
WBC count
more than 40 × 10
9/L, n (%) 5 (23.8)
median, ×109/L (range) 25.8 (3.5–90.2)
Platelets
more than 450 × 10
9/L, n (%) 8 (38.1)
median, ×10
9/L (range) 365.4 (140–863)
Peripheral blasts
1%–3%, n (%) 17 (80.9)
4% or more, n (%) 4 (19.1)
median, % (range) 2.43 (0–6)
Marrow basophils
4% or more, n (%) 4 (19.1)
median, % (range) 2.34 (0–10)
Marrow blasts
5% or more, n (%) 3 (14.3)
median, % (range) 2.8 (0–6.5)
Sokal risk
low, n (%) 10 (47.6)
intermediate, n (%) 9 (42.9)
high, n (%) 2 (9.5)
Table 2
Peripheral blood and bone marrow values in imatinib mesylate treated patients
Parameters 6 months 12 months 18 months 24 months
WBC count × 10
9/L, mean (range) 5.8 (3.4–10.5) 5.5 (3.7–8.3) 5.3 (4.1–8.2) 5.7 (4.6–7.5)
Platelet count × 10
9/L, mean (range) 215 (110–294) 171 (128–251) 188 (154–237) 196 (158–282)
Hemoglobin, g/L, mean (range) 130 (117–149) 123 (108–143) 136 (127–142) 128 (115–140)
Marrow basophil, % (range) 0.4 (0–1) 0.3 (0–1) 0.4 (0–1) 0.2 (0–1)
Marrow blasts, % (range) 1.8 (0–3) 1.3 (0–3) 1.1 (0–2) 0.7 (0–2)
Table 3
Cytogenetic response rate during imatinib mesylate treatment
Number of patients (%)
Cytogenetic response (CyR) 6 months 12 months 18 months 24 months
MajorCyR (CCyR+PCyR) 8 (57.14) 13 (92.9) 5 (100) 4 (80)
complete CyR (CCyR) 1 (7.14) 7  (50) 5 (100) 2 (40)
partial CyR (PCyR) 7 (50) 6 (42.9) 0 (0) 2 (40)
Minor CyR 6 (42.86) 1 (7.1) 0 (0) 0 (0)
Relapse 0 (0) 0 (0) 0 (0) 1 (10)
Of the subset of 14 patients in which cytogenetic re-
sponse was evaluated during the study period, best cytoge-
netic response rate at any time during study treatment to IM
was: major cytogenetic response attained in 13 (92.9%) pa-
tients and minor cytogenetic response attained in 1 (7.1%)
patient. Major cytogenetic response consisted of complete
cytogenetic response attained in 7 (50%) patients and partial
cytogenetic response attained in 6 (42.9%) patients.
Of 13 patients in whom a major cytogenetic response
was achieved, 4 (30.8%) continued to have such a response
as of last follow-up, whereas only 1 (7.7%) had a cytogenetic
relapse. The median time to cytogenetic relapse was 24
months from the start of the therapy and 18 months from the
initial achievement of a major cytogenetic response. No pa-
tient has progressed to accelerated or blastic phase and all
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Imatinib was generally well tolerated. The frequency of
adverse effects attributable to the drug is summarized in Ta-
ble 4. The most common nonhematologic adverse effects in-
cluded musculosceletal pain (23.5%), edema (17.6%), and
rash and related events (11.8%). Most adverse effects were
grade 1 (mild) or grade 2 (moderate). Imatinib can cause a
variety of hematologic toxic effects like anaemia, neutrope-
nia and trombocitopenia. One patient had a hematologic
toxic effect at grade 3/4, platelet count of less than 50 000
per mm
3. Daily dose was reduced to 300 mg because the pa-
tient had persisted at grade 3/4 for more than two weeks and
then treatment interrupted.
Discussion
Imatinib mesylate, a selective BCR-ABL tyrosine ki-
nase inhibitor, has revolutionized the treatment of Ph chro-
mosome – positive chronic myelogenous leukemia. Kantar-
jian et al. 
10–12 and O’Brien at al. 
13 present data demonstrat-
ing that imatinib is superior to interferon alfa plus cytarabine,
so it is now generally accepted that imatinib is the best initial
treatment for patients newly diagnosed with chronic myeloid
leukemia in chronic phase. The new agent formulated for
oral administration and then termed STI571 induced cytoge-
netic responses, some complete, in a high proportion of pa-
tients and had limited toxicity; the maximum tolerated dose
was not established, but a starting dose of 400 mg daily for
adults was recommended.
We compared our results with the results of IRIS study.
At phase 3 IRIS study with median follow-up of 19 months,
the estimated rates of complete hematologic response (CHR)
for patients treated with imatinib were 96%, major cytogenetic
response (MCyR) 87% and complete cytogenetic response
(CCyR) 76%. In the recently updated results of phase 3 IRIS
study, it was stated that with 5 years follow-up the estimated
cumulative best rates of CHR and CCyR were 98% and 87%,
respectively 
14, 15. In our analysis, we obtained similar findings,
With median follow-up of 12 months the estimated cumulative
best rates of CHR and MCyR were 90.48% and 92.9%, re-
spectively. On the other hand, cumulative best rate of CCyR
was 50%, which was lower than in IRIS sudy.
The results of our analysis, showing that 57.14% of the
patients achieved a MCyR by 6 months and 50% achieved
CCyR after 1 year, are similar to the results reported by
Goldman et al. 
15  that approximately 40% of the patients
achieved a MCyR by 6 months, and 65% achieved a CCyR
after 1 year of the therapy.
In this study imatinib was well-tolerated, and the most
nonhematological and hematological adverse effects were
grade 1 or 2 (mild or moderate), while 4.7% of patients in-
terrupted the treatment because of trombocitopenia grade
3/4. Our results are similar to those of Kantarjian et al. 
16,
showing that grade 3/4 nonhematologic toxic effects were
infrequent, hematologic toxic effects were manageable, and
only 2% of the patients discontinued the treatment because
of drug-related adverse events. No increase in rates of seri-
ous adverse events was observed with continuous use of the
drug for follow up periods, compared with earlier time
points.
Our results fully support the widely accepted conclusion
that the preferred initial treatment for newly diagnosed patients
in chronic phase CML should involve IM. Higher doses of
imatinib, alternative tyrosine kinase inhibitors such as da-
satinib or nilotinib and allogeneic stem cell transplantation are
implemented for suboptimal response or progression and are
under clinical evaluation as frontline approaches 
17–19.
Conclusion
After 2.5 years of follow-up, a continuous treatment of
chronic-phase CML with imatinib as initial therapy was
found to induce durable responses in a high proportion of the
evaluated patients. Our results confirm that imatinib is re-
markably safe and well-tolerated.
  Table 4
Adverse events related to treatment with imatinib mesylate
Adverse events Number of patients (%)
Edema 3 (17.5)
Musculosceletal pain 4 (23.5)
Rash and related events 2 (11.8)
Nausea/vomiting 2 (11.8)
Fatigue 1 (5.9)
Cardiac 1 (5.9)
Anemia 2 (11.8)
Neutropenia 1 (5.9)
Thrombocytopenia 1 (5.9)Strana 806 VOJNOSANITETSKI PREGLED Volumen 67, Broj 10
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